Recombinant soluble thrombomodulin: Coagulation takes another chance to reduce sepsis mortality

Journal of Thrombosis and Haemostasis

Volumn 13, Issue 4, 2015, Pages 505-507

  Levi, M ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVATED PROTEIN C; COMPLEMENT COMPONENT C3A; COMPLEMENT COMPONENT C5A; CYTOKINE; EPIDERMAL GROWTH FACTOR; FIBRIN; FIBRINOGEN; LECTIN; RECOMBINANT SOLUBLE THROMBOMODULIN; RECOMBINANT THROMBOMODULIN; THROMBIN; THROMBIN ACTIVATABLE FIBRINOLYSIS INHIBITOR; THROMBOMODULIN; UNCLASSIFIED DRUG; ANTICOAGULANT AGENT;

AMINO TERMINAL SEQUENCE; ANTIINFLAMMATORY ACTIVITY; BLEEDING; BLOOD CLOTTING; COMPLEMENT ACTIVATION; CYTOKINE RELEASE; DISEASE SEVERITY; DRUG MECHANISM; HUMAN; INFLAMMATION; INNATE IMMUNITY; META ANALYSIS (TOPIC); MORTALITY; NEUTROPHIL CHEMOTAXIS; NONHUMAN; NOTE; PRIORITY JOURNAL; PROTEIN DOMAIN; RANDOMIZED CONTROLLED TRIAL (TOPIC); SEPSIS; SYSTEMATIC REVIEW (TOPIC); DISSEMINATED INTRAVASCULAR COAGULATION;

ANTICOAGULANTS; DISSEMINATED INTRAVASCULAR COAGULATION; HUMANS; SEPSIS; THROMBOMODULIN;

EID: 84926115784     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/jth.12868     Document Type: Note

References (15)

1. Levi M, van der Poll T. Inflammation and coagulation. Crit Care Med 2010; 38: S26-34.
2. Angus DC, van der Poll T. Severe sepsis and septic shock. N Engl J Med 2013; 369: 840-51.
3. Warren BL, Eid A, Singer P, Pillay SS, Carl P, Novak I, Chalupa P, Atherstone A, Penzes I, Kubler A, Knaub S, Keinecke HO, Heinrichs H, Schindel F, Juers M, Bone RC, Opal SM. Caring for the critically ill patient. High-dose antithrombin III in severe sepsis: a randomized controlled trial. JAMA 2001; 286: 1869-78.
4. Abraham E, Reinhart K, Svoboda P, Seibert A, Olthoff D, Dal Nogare A, Postier R, Hempelmann G, Butler T, Martin E, Zwingelstein C, Percell S, Shu V, Leighton A, Creasey AA. Assessment of the safety of recombinant tissue factor pathway inhibitor in patients with severe sepsis: a multicenter, randomized, placebo-controlled, single-blind, dose escalation study. Crit Care Med 2001; 29: 2081-9.
5. Bernard GR, Vincent JL, Laterre PF, LaRosa SP, Dhainaut JF, Lopez-Rodriguez A, Steingrub JS, Garber GE, Helterbrand JD, Ely EW, Fisher CJJ. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 2001; 344: 699-709.
6. Levi M, Schultz M, van der Poll T. Sepsis and thrombosis. Semin Thromb Hemost 2013; 39: 559-66.
7. Ranieri VM, Thompson BT, Barie PS, Dhainaut JF, Douglas IS, Finfer S, Gårdlund B, Marshall JC, Rhodes A, Artigas A, Payen D, Tenhunen J, Al-Khalidi HR, Thompson V, Janes J, Macias WL, Vangerow B, Williams MD. Drotrecogin Alfa (Activated) in Adults with Septic Shock. N Engl J Med 2012; 366: 2055-64.
8. Levi M, van der Poll T. Thrombomodulin in sepsis. Minerva Anestesiol 2013; 79: 294-8.
9. Yamakawa K, Aihara M, Ogura H, Yuhara H, Hamasaki T, Shimazu T. Recombinant human soluble thrombomodulin in severe sepsis: a systematic review and meta-analysis. J Thromb Haemost 2015; 13: 508-19.
10. Dhainaut JF, Yan SB, Joyce DE, Pettila V, Basson BR, Brandt JT, Sundin D, Levi M. Treatment effects of drotrecogin alfa (activated) in patients with severe sepsis with or without overt disseminated intravascular coagulation. J Thromb Haemost 2004; 2: 1924-33.
11. Schouten M, de Boer JD, van 't Veer C, Roelofs JJ, Meijers JC, Levi M, Conway EM, van der Poll T. The lectin-like domain of thrombomodulin hampers host defense in pneumococcal pneumonia. Eur Respir J 2012; 41: 935-42.
12. Conway EM. Thrombomodulin and its role in inflammation. Semin Immunopathol 2012; 34: 107-25.
13. Esmon CT. New mechanisms for vascular control of inflammation mediated by natural anticoagulant proteins. J Exp Med 2002; 196: 561-4.
14. Zushi M, Gomi K, Yamamoto S, Maruyama I, Hayashi T, Suzuki K. The last three consecutive epidermal growth factor-like structures of human thrombomodulin comprise the minimum functional domain for protein C-activating cofactor activity and anticoagulant activity. J Biol Chem 1989; 264: 10351-3.
15. Tagami T, Matsui H, Horiguchi H, Fushimi K, Yasunaga H. Recombinant human soluble thrombomodulin and mortality in severe pneumonia patients with sepsis-associated disseminated intravascular coagulation: an observational nationwide study. J Thromb Haemost 2014; 12: 1-10.